Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 16/20 | 0.76 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.60 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.60 |
| ▸ | GRK5 | P34947 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039458 | 0.87 | S1PR5 (1.00) | S1PR5S1PR1S1PR3 | |
| SCHEMBL16695243 | 0.84 | S1PR5 (0.82) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL565212 | 0.84 | S1PR5 (0.87) | S1PR5S1PR1S1PR3S1PR4GRK5 | |
| SCHEMBL6994717 | 0.83 | HTR2A (0.64) | S1PR5 | |
| SCHEMBL3933586 | 0.83 | S1PR5 (0.69) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL13215741 | 0.83 | S1PR5 (0.91) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL9915003 | 0.83 | S1PR5 (0.91) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL23232297 | 0.82 | S1PR5 (0.64) | S1PR5S1PR1HTTS1PR3S1PR4 | |
| SCHEMBL3040582 | 0.82 | S1PR5 (0.69) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL3027737 | 0.81 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4GRK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181246-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140357616-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-8822446-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2014-09-02 | — | — | US | disclosed |
| EP-2454257-B1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8435980-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2560971-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2454257-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011133388-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110257152-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2011008915-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | S1PR5 2992/4885S1PR1 2678/4885HTT 3816/4885 |
| US-20140357616-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | S1PR5 2992/4885S1PR1 2678/4885HTT 3816/4885 |
| US-20110257152-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | S1PR5 2992/4885S1PR1 2678/4885HTT 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.